#TalkingRegMed episode 6: Brexit with Matthew Durdy, Cell and Gene Therapy Catapult

Written by RegMedNet

In this episode of #TalkingRegMed, Matthew Durdy, Chief Business Officer, Cell and Gene Therapy Catapult, explains the effect of Brexit on cell therapy development in the UK.

In this episode of #TalkingRegMed, hear from Matthew Durdy, Chief Business Officer, Cell and Gene Therapy Catapult, on how Brexit may effect the cell therapy industry in the UK. In particular, he discusses what other avenues are being explored to ensure Britain remains on the world stage in this industry.

Watch more #TalkingRegMed